Cipher Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cipher Pharmaceuticals Inc.
Private Company Edition: Quarter-over-quarter increases in venture capital have been bolstered by fewer but larger rounds, like the recent $245m series A for Aiolos. Also, OrbiMed raised $4.3bn across three new VC funds, Rampart completed an $85m series A and Atom Bioscience raised an $83m series D.
Sans Sandoz, Novartis posts a beat-and-raise but its oncology franchise remains undistinguished.
Public Company Edition: Neumora grossed $250m and RayzeBio raised $311m in the first initial public offerings since early August. Also, ImmunityBio completes $470m in equity and debt financings, Bausch + Lomb sells $1.4bn worth of notes and Arbutus is among firms making cuts to conserve cash.
A pivotal miss leaves the company more reliant on earlier-stage pipeline programs as it talks to regulators about the path forward for its lead product.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Innocutis Medical LLC (Innocutis Holding LLC
- JSJ Pharmaceuticals)
- Cipher Pharmaceuticals US LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.